Oral ARV-110 Shows Promise in Heavily Treated mCRPC Patients
News
ARV-110, an investigational oral therapy that degrades the androgen receptor, has a favorable safety profile and showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC), ... Read more